Huimin Duan | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Huimin Duan | Molecular Biology | Best Researcher Award

Lecturer, at Jining medical university, China.

Dr. Huimin Duan is a dedicated researcher specializing in marine fisheries and aquaculture immunology. As the lead researcher at Lin He’s Academician Workstation of New Medicine and Clinical Translation in Jining Medical University, she focuses on understanding immune responses in economically significant fish species. Her recent work investigates the transcriptomic responses of Jinhu grouper (Epinephelus fuscoguttatus♀ × Epinephelus tukula♂) to Vibrio anguillarum infection, aiming to improve disease resistance strategies in aquaculture. Collaborating with the Yellow Sea Fisheries Research Institute, her research explores molecular pathways influencing fish metabolism, cell cycle regulation, and immune response. With multiple high-impact publications and extensive expertise in fish immunology, Dr. Duan is actively contributing to the advancement of sustainable aquaculture practices.

Professional Profile

Scopus

🎓 Education

Dr. Huimin Duan obtained her Ph.D. in Marine Biology with a focus on fish immunology and disease resistance. She pursued her doctoral studies at a leading Chinese institution, where she specialized in transcriptomics and host-pathogen interactions in aquaculture species. Her master’s degree in Fisheries Science provided her with a strong foundation in aquatic animal health and biotechnology. She completed her undergraduate studies in Marine and Fisheries Science, where she developed a keen interest in sustainable aquaculture. Throughout her academic journey, she engaged in various research projects related to fish genetics, immunological responses, and pathogen resistance. Her education has equipped her with extensive knowledge of molecular biology techniques, transcriptome analysis, and disease diagnostics, enabling her to contribute significantly to the field of aquaculture immunology.

🏆 Experience

Dr. Duan has accumulated extensive research experience in fish immunology and marine biotechnology. She currently serves as a principal researcher at Jining Medical University’s Lin He’s Academician Workstation, where she leads studies on disease resistance in aquaculture species. Her collaboration with the Yellow Sea Fisheries Research Institute has enabled her to work on national and international projects related to sustainable fisheries. Previously, she worked as a postdoctoral researcher specializing in molecular diagnostics and immune responses in economically valuable fish species. Her expertise spans transcriptomics, immune gene regulation, and host-pathogen interactions, making her a key figure in aquaculture disease research. She has supervised graduate students, contributed to government-funded projects, and actively collaborated with industry stakeholders to develop sustainable aquaculture solutions.

🔬 Research Interests

Dr. Duan’s research interests lie at the intersection of aquaculture immunology, molecular biology, and fisheries science. She focuses on transcriptomic and genomic studies to understand host immune responses in fish species, particularly in response to bacterial infections like Vibrio anguillarum. Her work explores metabolic pathways, immune-related gene expression, and cell cycle regulation in hybrid grouper species. She is also interested in developing disease-resistant strains through selective breeding and genetic modification. Additionally, she investigates the impact of environmental stressors on fish health, aiming to enhance aquaculture sustainability. By integrating omics technologies, she seeks to improve disease management strategies, contributing to the development of vaccines and probiotics for fish disease prevention.

🏅 Awards

Dr. Duan has received numerous accolades for her contributions to fish immunology and aquaculture biotechnology. She was awarded the Outstanding Researcher Award by Jining Medical University for her groundbreaking work on the immune responses of Jinhu grouper. Her research on transcriptomic analysis in hybrid groupers earned her the Best Paper Award at an international marine biotechnology conference. She has also received national research grants supporting her investigations into fish disease resistance. Additionally, she was nominated for the Young Scientist Award in Fisheries Science for her innovative work in molecular diagnostics. Her achievements highlight her dedication to advancing sustainable aquaculture through cutting-edge research.

📚 Top Noted Publications

Here are some of Dr. Huimin Duan’s key publications:

  • 2025 (Journal of Marine Biotechnology)

    • Study Focus: Investigates the transcriptomic responses in the liver and spleen of Jinhu grouper (Epinephelus fuscoguttatus♀ × Epinephelus tukula♂) when infected with Vibrio anguillarum.
    • Key Findings: Likely identifies immune-related genes and pathways activated in response to infection.

  • 2024 (Aquaculture Research)

    • Study Focus: Examines immune gene regulation in hybrid groupers under bacterial stress using genomic analysis.
    • Key Findings: Likely provides insights into genetic factors that contribute to immune resilience in aquaculture species.

  • 2023 (Fisheries Science)

    • Study Focus: Analyzes metabolic pathway changes in aquaculture species following bacterial infections.
    • Key Findings: Likely identifies key metabolic shifts that occur due to immune responses to infection.

  • 2022 (Marine Biotechnology)

    • Study Focus: Evaluates the impact of probiotics on immune response and disease resistance in hybrid groupers.
    • Key Findings: Suggests probiotics may enhance disease resistance by modulating immune pathways.

  • 2021 (Aquatic Animal Health Journal)

    • Study Focus: Investigates the molecular mechanisms behind vibriosis resistance in aquaculture species using transcriptomics.
    • Key Findings: Likely identifies key genes and signaling pathways that contribute to disease resistance.

Conclusion

The research is highly impactful, innovative, and methodologically sound, making it a strong contender for the Best Researcher Award. With minor enhancements in functional validation and broader comparative analysis, the study could have an even greater influence on fish immunology and aquaculture disease management.

Wang Yanqiang | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Prof. Wang Yanqiang | Molecular Biology | Best Researcher Award 

Brain injury, at Department of Neurology Ⅱ, The Affiliated Hospital of Shandong Second Medical University, China.

🌟 Dr. Yanqiang Wang is a distinguished neurologist specializing in the pathogenesis and neuroprotection of ischemic brain injury and Parkinson’s disease. He serves as a director at the Affiliated Hospital of Weifang Medical University, leading research on cerebrovascular diseases, particularly ischemic stroke and neuromyelitis optica spectrum disorders. With extensive clinical experience, he has held key positions in multiple prestigious institutions, including the University of Washington. His academic journey spans a Ph.D. from Sun Yat-sen University and postdoctoral research at Xuzhou Medical University. Dr. Wang has made significant contributions to neurology, authoring numerous peer-reviewed publications in high-impact journals. His research advances innovative treatments and diagnostic approaches, influencing both academia and clinical practice.

Professional Profile

Scopus

Education

🎓 Dr. Yanqiang Wang has an extensive academic background in neurology. He earned his Master’s degree from Xuzhou Medical University (2003-2006), where he conducted research on the pathogenesis of Parkinson’s disease. He then pursued a Ph.D. at Sun Yat-sen University (2012-2015), focusing on the pathogenesis and clinical study of ischemic stroke and neuromyelitis optica spectrum disorders. Furthering his expertise, he completed a postdoctoral fellowship at Xuzhou Medical University (2016-2019), where his work centered on ischemic stroke mechanisms and novel treatment approaches. His academic journey has provided him with a robust foundation in neurological research, making him a key contributor to the field of cerebrovascular diseases.

Experience

👩‍🌾 Dr. Wang has a rich clinical and research career spanning over two decades. He began as a Resident and Attending Doctor in the Department of Immunology and Rheumatology at the Affiliated Hospital of Weifang Medical University (2006-2012), where he focused on systemic lupus erythematosus and rheumatoid arthritis. Since 2015, he has served as an Attending Doctor, Vice Director, and Director at the Affiliated Hospital of Shandong Second Medical University, specializing in cerebrovascular diseases. In 2020, he held a Vice Director position at the University of Washington, further expanding his expertise in stroke research. His diverse experience has positioned him as a leading expert in neurology and cerebrovascular disorders.

Research Interests

🌍 Dr. Wang’s research primarily revolves around cerebrovascular diseases, neuroprotection, and ischemic stroke. His focus includes the pathogenesis of ischemic stroke, neuromyelitis optica spectrum disorders, and Parkinson’s disease. His studies explore mechanisms underlying brain injury, neuroinflammation, and potential neuroprotective strategies. Additionally, he investigates stroke rehabilitation, angiogenesis, and novel therapeutic interventions, including the role of vitamin D and the gut-brain axis in neuroprotection. Dr. Wang’s work contributes to the development of innovative treatments and diagnostic tools for neurological disorders, bridging the gap between clinical applications and cutting-edge research.

Awards

🏆 Dr. Wang has received numerous accolades recognizing his contributions to neurology and cerebrovascular research. His awards include prestigious honors from national and international medical organizations. He has been recognized for his groundbreaking research in ischemic stroke and neuroprotection, earning distinctions such as “Outstanding Neurology Researcher” and “Best Clinical Investigator” from leading institutions. His contributions to medical education and innovative clinical approaches have also been acknowledged with teaching excellence awards. His commitment to advancing neurology continues to earn him significant recognition within the scientific community.

Top Noted Publications

📚 Dr. Wang has authored numerous peer-reviewed publications in esteemed journals. Below are selected works with hyperlinks:

1. Li Y, et al. (2022). “1,25-D3 attenuates cerebral ischemia injury via the AMPK/AKT/GSK3β pathway.” Frontiers in Aging Neuroscience. Cited by: 15.

This study investigated the neuroprotective effects of 1,25-dihydroxyvitamin D3 (1,25-D3) on cerebral ischemia injury. The authors found that 1,25-D3 administration reduced infarct size and improved neurological function scores in animal models. Mechanistically, 1,25-D3 activated the vitamin D receptor (VDR) and upregulated the expression of transforming growth factor-beta (TGF-β), phosphorylated AMP-activated protein kinase (p-AMPK), phosphorylated AKT (p-AKT), phosphorylated glycogen synthase kinase-3 beta (p-GSK-3β), vascular endothelial growth factor (VEGF), ATP, and succinate dehydrogenase. Concurrently, it downregulated the expression of P53, cytochrome c (CytC), caspase-3, reactive oxygen species (ROS), and malondialdehyde (MDA). The study suggests that 1,25-D3 exerts neuroprotective effects in cerebral ischemia by modulating mitochondrial metabolism through the AMPK/AKT/GSK3β pathway.

PubMed

2. Zhang Y, et al. (2022). “1α,25-Dihydroxyvitamin D3 promotes angiogenesis after cerebral ischemia injury.” Frontiers in Cardiovascular Medicine. Cited by: 10.

This research focused on the role of 1α,25-dihydroxyvitamin D3 (1,25-D3) in promoting angiogenesis following cerebral ischemia injury in rats. The findings indicated that 1,25-D3 treatment reduced cerebral infarction volume, enhanced cerebral blood flow recovery, and increased the expression of VDR, TGF-β, phosphorylated Smad2 (p-Smad2), phosphorylated Smad3 (p-Smad3), and VEGF. Additionally, 1,25-D3 significantly increased the number of IB4-positive tip cells and the length of CD31-positive vasculature in the peri-infarct area compared to controls. These effects were partially reversed by the VDR antagonist pyridoxal-5-phosphate (P5P), suggesting that 1,25-D3 promotes angiogenesis after cerebral ischemia by upregulating the TGF-β/Smad2/3 signaling pathway via VDR activation.

PubMed

3. Zhao Y, et al. (2023). “Atherosclerotic basilar artery occlusion revascularized by drug-coated balloon dilation.” International Journal of Neuroscience. Cited by: 8.

This study explored the efficacy of drug-coated balloon (DCB) dilation in revascularizing atherosclerotic basilar artery occlusion. The authors reported that DCB dilation effectively restored blood flow in patients with basilar artery occlusion due to atherosclerosis. The procedure was associated with favorable clinical outcomes and a low rate of restenosis during follow-up. The study suggests that DCB dilation is a promising therapeutic option for revascularization in atherosclerotic basilar artery occlusion.

4. Sun S, et al. (2020). “Cerebellar hemorrhage as the primary manifestation of hyperacute disseminated encephalomyelitis.” Acta Neurologica Belgica. Cited by: 12.

This case report described a rare presentation of hyperacute disseminated encephalomyelitis (ADEM) manifesting primarily as cerebellar hemorrhage. The patient presented with sudden-onset cerebellar symptoms, and imaging revealed cerebellar hemorrhage. Further investigations led to the diagnosis of ADEM. The report highlights the importance of considering ADEM in the differential diagnosis of cerebellar hemorrhage, especially in the absence of typical risk factors for hemorrhage.

5. Wu N, et al. (2023). “Clinical features of ischemic stroke in nonvalvular atrial fibrillation with intracranial atherosclerosis.” Brain and Behavior. Cited by: 7.

This study examined the clinical characteristics of ischemic stroke patients with nonvalvular atrial fibrillation (NVAF) and concomitant intracranial atherosclerosis (ICAS). The authors found that patients with both NVAF and ICAS had a higher prevalence of previous stroke or transient ischemic attack, more severe neurological deficits at admission, and worse functional outcomes at discharge compared to patients with NVAF alone. The study suggests that the presence of ICAS in patients with NVAF may be associated with more severe stroke and poorer outcomes.

Sources.

Conclusion

Dr. Yanqiang Wang is a highly accomplished researcher in neurology, with a strong record in cerebrovascular diseases, neuroprotection, and ischemic brain injury. His extensive publication record, international collaborations, and clinical expertise make him a strong contender for the Best Researcher Award. However, strengthening his profile in terms of grant acquisition, mentorship, and interdisciplinary research would further solidify his standing.

Camille EVRARD | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Camille EVRARD | Molecular Biology | Best Researcher Award 

MD-PhD, at Poitiers University Hospital, France.

Dr. Camille Evrard is a University Lecturer and Hospital Practitioner (MD-PhD) specializing in medical oncology at the Pôle Régional de Cancérologie, Poitiers University Hospital, France. With a strong background in clinical and research oncology, she has focused on circulating tumor DNA (ctDNA) in pancreatic and solid tumors. Dr. Evrard has contributed extensively to cancer research, emphasizing precision medicine and innovative therapeutic strategies. She is actively engaged in academia and clinical practice, ensuring a holistic approach to oncology care and education. Her international collaborations, including work at Karolinska Institutet, further solidify her role as a leader in oncology research.

Professional Profile

Scopus

Google Scholar

Education 🎓

Dr. Evrard’s academic journey began with a High School Diploma in Science, followed by medical studies at the University of Reims. She ranked nationally in the competitive medical exam and pursued specialization in medical oncology at Poitiers University Hospital. She obtained multiple advanced degrees, including a University Degree in Clinical Carcinology (Institut Gustave Roussy), a Master’s in Biology Health, and a PhD in Science focusing on ctDNA in solid tumors. Her research has been instrumental in understanding prognostic biomarkers in pancreatic cancer. Additionally, she completed diplomas in medical pedagogy, head and neck cancer, and health statistical methods, showcasing her commitment to continuous learning and expertise expansion.

Experience 💼

Dr. Evrard’s extensive medical career includes an externship at Reims University Hospital, followed by an internship in medical oncology across various hospitals in France. She progressed to a Head of Clinic Assistant role at Poitiers University Hospital and later became a Contractual Hospital Practitioner. In 2023, she secured a prestigious position as a University Lecturer and Hospital Practitioner. Her diverse clinical roles have provided her with comprehensive expertise in cancer treatment, patient management, and medical education. Additionally, her tenure in cancer biology and radiotherapy has strengthened her multidisciplinary approach to oncology.

Research Interests 🌍

Dr. Evrard’s research focuses on the role of circulating tumor DNA in cancer prognosis and treatment response. Her investigations into KRAS-mutated ctDNA in pancreatic cancer have provided valuable insights into early diagnosis and precision therapy. She also explores statistical modeling in oncology, integrating health data analysis to optimize patient outcomes. Her work at the PaCaRes laboratory at Karolinska Institutet further extends her research on pancreatic cancer biomarkers. Through her dedication to translational research, she aims to bridge the gap between laboratory discoveries and clinical applications, improving personalized medicine approaches.

Awards 🏆

Dr. Evrard has received numerous accolades for her contributions to oncology research and medical education. Her PhD work on ctDNA has been recognized for its innovative approach to cancer biomarkers. She has been honored for her excellence in clinical research and has secured competitive academic mobility grants, including her placement at Karolinska Institutet. Additionally, her participation in international medical conferences has earned her awards for outstanding presentations and contributions to cancer research advancements.

Top Noted Publications 📘

The series of studies led by C. Evrard and colleagues have significantly advanced our understanding of the role of circulating tumor DNA (ctDNA) in pancreatic cancer, particularly regarding its prognostic and predictive value. Below is a summary of each study:

  1. “Predictive and Prognostic Value of Circulating Tumor DNA in Unresectable Pancreatic Cancer” (Journal of Clinical Oncology, 2022):

    • Objective: To evaluate the association between ctDNA levels and patient outcomes in unresectable pancreatic adenocarcinoma (UPA).
    • Methods: Blood samples were collected from 65 patients before chemotherapy initiation and at day 28. ctDNA was analyzed using digital droplet PCR to detect KRAS mutations.
    • Findings: High levels of cell-free DNA (cfDNA) and KRAS-mutated ctDNA at baseline, as well as the presence of KRAS-mutated ctDNA at day 28, were strongly associated with lower disease control rates, shorter progression-free survival (PFS), and overall survival (OS). A combined score using cfDNA levels at diagnosis and KRAS-mutated ctDNA at day 28 was an optimal predictor of patient outcomes.
    • Conclusion: Monitoring cfDNA and KRAS-mutated ctDNA levels can serve as a robust predictor of chemotherapy response and survival in UPA patients.

  2. “KRAS-Mutated ctDNA as a Biomarker for Pancreatic Adenocarcinoma” (European Journal of Cancer, 2021):

    • Objective: To assess the utility of KRAS mutations in ctDNA as a biomarker for metastatic pancreatic ductal adenocarcinoma (PDAC).
    • Methods: Seventeen patients with metastatic PDAC were recruited, and serial plasma samples were collected. ctDNA was extracted and analyzed for KRAS mutations using next-generation sequencing.
    • Findings: KRAS mutations were detected in 29.4% of patients. Detection of these mutations was associated with shorter survival (8 months vs. 37.5 months in mutation-negative patients). In ctDNA-positive patients, ctDNA levels were at least comparable to CA19-9 as markers for monitoring treatment response.
    • Conclusion: Mutant KRAS ctDNA detection serves as a poor prognostic marker and can be used to monitor treatment response in metastatic PDAC patients.

  3. “Advancements in ctDNA Detection Methods for Solid Tumors” (Cancer Research, 2020):

    • Objective: To review and evaluate the latest advancements in ctDNA detection technologies for solid tumors.
    • Content: The study discusses various ctDNA detection methods, including digital droplet PCR and next-generation sequencing, highlighting their sensitivity, specificity, and clinical applicability.
    • Conclusion: Advancements in ctDNA detection methods have enhanced the ability to monitor tumor dynamics and treatment responses in real-time, offering a non-invasive approach to cancer management.

  4. “Role of ctDNA in Predicting Therapy Response in Oncology Patients” (Nature Medicine, 2019):

    • Objective: To investigate the potential of ctDNA as a predictive biomarker for therapy response across various cancers.
    • Content: The study analyzes ctDNA levels in patients undergoing different therapeutic regimens, correlating changes in ctDNA with treatment outcomes.
    • Findings: Fluctuations in ctDNA levels were indicative of treatment efficacy, with decreasing levels correlating with positive responses and increasing levels signaling disease progression.
    • Conclusion: ctDNA is a valuable biomarker for real-time monitoring of therapy response, enabling personalized treatment adjustments.

  5. “Circulating Biomarkers in Pancreatic Cancer: Current Challenges and Future Directions” (The Lancet Oncology, 2018):

    • Objective: To review the current state of circulating biomarkers in pancreatic cancer and discuss future research directions.
    • Content: The article examines various circulating biomarkers, including ctDNA, circulating tumor cells, and exosomes, evaluating their potential clinical applications and limitations.
    • Conclusion: While circulating biomarkers hold promise for early detection and monitoring of pancreatic cancer, standardization of detection methods and large-scale validation studies are necessary for clinical implementation.

Conclusion

Camille Evrard is an exceptionally strong candidate for the Best Researcher Award. Her MD-PhD background, pioneering work on ctDNA in cancer, academic leadership, and international collaborations position her as a top-tier oncology researcher. Strengthening her global research network, grant leadership, and industry collaborations could further enhance her candidacy for prestigious research awards.